{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:44:39Z","timestamp":1792928679048,"version":"4.5.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T00:00:00Z","timestamp":1736380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SH2 (Src Homology 2) domains play a crucial role in phosphotyrosine-mediated signaling and have emerged as promising drug targets, particularly in cancer therapy. STAT3 (Signal Transducer and Activator of Transcription 3), which contains an SH2 domain, plays a pivotal role in cancer progression and immune evasion because it facilitates the dimerization of STAT3, which is essential for their activation and subsequent nuclear translocation. SH2 domain-mediated STAT3 inhibition disrupts this binding, reduces phosphorylation of STAT3, and impairs dimerization. This study employed an in silico approach to screen potential natural compounds that could target the SH2 domain of STAT3 and inhibit its function. The phytomolecules (182455) were retrieved from the ZINC 15 database and were docked using various modes like HTVS, SP, and XP. The phytomolecules exhibiting higher binding affinity were selected. MM-GBSA was performed to determine binding free energy, and the QikProp tool was utilized to assess the pharmacokinetic properties of potential hit compounds, narrowing down the list of candidates. Molecular dynamics simulations, thermal MM-GBSA, and WaterMap analysis were performed on compounds that exhibited favorable binding affinities and pharmacokinetic characteristics. Based on docking scores and binding interactions, ZINC255200449, ZINC299817570, ZINC31167114, and ZINC67910988 were identified as potential STAT3 inhibitors. ZINC67910988 demonstrated superior stability in molecular dynamics simulation and WaterMap analysis. Furthermore, DFT was performed to determine energetic and electronic properties, and HOMO and LUMO sites were predicted for electronic structure calculation. Additionally, network pharmacology was performed to map the compounds\u2019 interactions within biological networks, highlighting their multitarget potential. Compound-target networks elucidate the relationships between compounds and multiple targets, along with their associated pathways and help to minimize off-target effects. The identified lead compound showed strong potential as a STAT3 inhibitor, warranting further validation through in vitro and in vivo studies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s11030-024-11075-5","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T04:32:00Z","timestamp":1736397120000},"page":"5607-5633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Computational screening and molecular dynamics of natural compounds targeting the SH2 domain of STAT3: a multitarget approach using network pharmacology"],"prefix":"10.1007","volume":"29","author":[{"given":"Sachindra","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Harish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samyak","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Sreedhara Ranganath","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"11075_CR1","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/cancers6020926","volume":"6","author":"A Xiong","year":"2014","unstructured":"Xiong A, Yang Z, Shen Y et al (2014) Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel) 6:926\u2013957. https:\/\/doi.org\/10.3390\/cancers6020926","journal-title":"Cancers (Basel)"},{"key":"11075_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/01.cji.0000211327.76266.65","volume":"30","author":"M Kortylewski","year":"2007","unstructured":"Kortylewski M, Yu H (2007) Stat3 as a potential target for cancer immunotherapy. J Immunother 30:131\u2013139. https:\/\/doi.org\/10.1097\/01.cji.0000211327.76266.65","journal-title":"J Immunother"},{"key":"11075_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4236\/jct.2015.68078","volume":"06","author":"I Gkouveris","year":"2015","unstructured":"Gkouveris I, Nikitakis N, Sauk J (2015) STAT3 signaling in cancer. J Cancer Ther 06:709\u2013726. https:\/\/doi.org\/10.4236\/jct.2015.68078","journal-title":"J Cancer Ther"},{"key":"11075_CR4","doi-asserted-by":"publisher","first-page":"16975","DOI":"10.1073\/pnas.1315862110","volume":"110","author":"Y Wang","year":"2013","unstructured":"Wang Y, van Boxel-Dezaire AHH, Cheon H et al (2013) STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci 110:16975\u201316980. https:\/\/doi.org\/10.1073\/pnas.1315862110","journal-title":"Proc Natl Acad Sci"},{"key":"11075_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo H-W (2014) STAT3 target genes relevant to human cancers. Cancers (Basel) 6:897\u2013925. https:\/\/doi.org\/10.3390\/cancers6020897","journal-title":"Cancers (Basel)"},{"key":"11075_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/mi.11.1.4","volume":"11","author":"PA Johnston","year":"2011","unstructured":"Johnston PA, Grandis JR (2011) STAT3 signaling: anticancer strategies and challenges. Mol Interv 11:18\u201326. https:\/\/doi.org\/10.1124\/mi.11.1.4","journal-title":"Mol Interv"},{"key":"11075_CR7","doi-asserted-by":"publisher","first-page":"7132","DOI":"10.1128\/MCB.20.19.7132-7139.2000","volume":"20","author":"T Zhang","year":"2000","unstructured":"Zhang T, Kee WH, Seow KT et al (2000) The coiled-coil domain of Stat3 Is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol Cell Biol 20:7132\u20137139. https:\/\/doi.org\/10.1128\/MCB.20.19.7132-7139.2000","journal-title":"Mol Cell Biol"},{"key":"11075_CR8","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/cancers11111681","volume":"11","author":"Y-TK Lau","year":"2019","unstructured":"Lau Y-TK, Ramaiyer M, Johnson DE, Grandis JR (2019) Targeting STAT3 in cancer with nucleotide therapeutics. Cancers (Basel) 11:1681. https:\/\/doi.org\/10.3390\/cancers11111681","journal-title":"Cancers (Basel)"},{"key":"11075_CR9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0092-8674(00)81959-5","volume":"98","author":"JF Bromberg","year":"1999","unstructured":"Bromberg JF, Wrzeszczynska MH, Devgan G et al (1999) Stat3 as an oncogene. Cell 98:295\u2013303. https:\/\/doi.org\/10.1016\/S0092-8674(00)81959-5","journal-title":"Cell"},{"key":"11075_CR10","doi-asserted-by":"publisher","first-page":"20147","DOI":"10.1038\/s41598-023-46193-x","volume":"13","author":"H Rafiq","year":"2023","unstructured":"Rafiq H, Hu J, Hakami MA et al (2023) Identification of novel STAT3 inhibitors for liver fibrosis, using pharmacophore-based virtual screening, molecular docking, and biomolecular dynamics simulations. Sci Rep 13:20147. https:\/\/doi.org\/10.1038\/s41598-023-46193-x","journal-title":"Sci Rep"},{"key":"11075_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1142\/S2737416523500588","volume":"23","author":"S Gul","year":"2024","unstructured":"Gul S, Muhammad S, Irfan M et al (2024) Discovery of potential natural STAT3 inhibitors: an in silico molecular docking and molecular dynamics study. J Comput Biophys Chem 23:189\u2013205. https:\/\/doi.org\/10.1142\/S2737416523500588","journal-title":"J Comput Biophys Chem"},{"key":"11075_CR12","doi-asserted-by":"publisher","first-page":"e17908","DOI":"10.1016\/j.heliyon.2023.e17908","volume":"9","author":"P Lin","year":"2023","unstructured":"Lin P, Weng T, Duan L et al (2023) Protective effects and regulatory mechanisms of Shen-shuai-yi recipe on renal fibrosis in unilateral ureteral obstruction-induced mice. Heliyon 9:e17908. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17908","journal-title":"Heliyon"},{"key":"11075_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai L, Zhou H, Xu R et al (2019) A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36:498-511.e17. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.002","journal-title":"Cancer Cell"},{"key":"11075_CR14","doi-asserted-by":"publisher","first-page":"W542","DOI":"10.1093\/nar\/gkad420","volume":"51","author":"D Bajusz","year":"2023","unstructured":"Bajusz D, P\u00e1ndy-Szekeres G, Tak\u00e1cs \u00c1 et al (2023) SH2db, an information system for the SH2 domain. Nucleic Acids Res 51:W542\u2013W552. https:\/\/doi.org\/10.1093\/nar\/gkad420","journal-title":"Nucleic Acids Res"},{"key":"11075_CR15","doi-asserted-by":"publisher","first-page":"105637","DOI":"10.1016\/j.phrs.2021.105637","volume":"169","author":"R Kong","year":"2021","unstructured":"Kong R, Bharadwaj U, Eckols TK et al (2021) Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility. Pharmacol Res 169:105637. https:\/\/doi.org\/10.1016\/j.phrs.2021.105637","journal-title":"Pharmacol Res"},{"key":"11075_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/B978-0-12-369441-6.00024-6","volume-title":"Signal transduction","author":"BD Gomperts","year":"2009","unstructured":"Gomperts BD, IjM K, Tatham PER (2009) Protein domains and signal transduction. In: Signal transduction. Elsevier, Amsterdam, pp 763\u2013790"},{"key":"11075_CR17","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1038\/s41598-017-02671-7","volume":"7","author":"H-Y Qiu","year":"2017","unstructured":"Qiu H-Y, Zhu X, Luo Y-L et al (2017) Identification of new shikonin derivatives as antitumor agents targeting STAT3 SH2 domain. Sci Rep 7:2863. https:\/\/doi.org\/10.1038\/s41598-017-02671-7","journal-title":"Sci Rep"},{"key":"11075_CR18","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","volume":"13","author":"J Schust","year":"2006","unstructured":"Schust J, Sperl B, Hollis A et al (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13:1235\u20131242. https:\/\/doi.org\/10.1016\/j.chembiol.2006.09.018","journal-title":"Chem Biol"},{"key":"11075_CR19","doi-asserted-by":"publisher","first-page":"8261","DOI":"10.1111\/jcmm.16754","volume":"25","author":"S Kong","year":"2021","unstructured":"Kong S, Ge X, Li X et al (2021) SD-36 promotes growth inhibition and induces apoptosis via suppression of Mcl-1 in glioma. J Cell Mol Med 25:8261\u20138270. https:\/\/doi.org\/10.1111\/jcmm.16754","journal-title":"J Cell Mol Med"},{"key":"11075_CR20","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","volume":"13","author":"PC Agu","year":"2023","unstructured":"Agu PC, Afiukwa CA, Orji OU et al (2023) Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep 13:13398. https:\/\/doi.org\/10.1038\/s41598-023-40160-2","journal-title":"Sci Rep"},{"key":"11075_CR21","doi-asserted-by":"publisher","first-page":"11104","DOI":"10.1002\/jcb.28387","volume":"120","author":"G Tanwar","year":"2019","unstructured":"Tanwar G, Purohit R (2019) Gain of native conformation of Aurora A S155R mutant by small molecules. J Cell Biochem 120:11104\u201311114. https:\/\/doi.org\/10.1002\/jcb.28387","journal-title":"J Cell Biochem"},{"key":"11075_CR22","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1080\/07391102.2021.1900918","volume":"40","author":"R Singh","year":"2022","unstructured":"Singh R, Bhardwaj VK, Sharma J et al (2022) Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration. J Biomol Struct Dyn 40:7693\u20137701. https:\/\/doi.org\/10.1080\/07391102.2021.1900918","journal-title":"J Biomol Struct Dyn"},{"key":"11075_CR23","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.3390\/ijms20184331","volume":"20","author":"L Pinzi","year":"2019","unstructured":"Pinzi L, Rastelli G (2019) Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci 20:4331. https:\/\/doi.org\/10.3390\/ijms20184331","journal-title":"Int J Mol Sci"},{"key":"11075_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.crvi.2008.03.004","volume":"331","author":"R Rajasekaran","year":"2008","unstructured":"Rajasekaran R, George Priya Doss C, Sudandiradoss C et al (2008) Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C R Biol 331:409\u2013417. https:\/\/doi.org\/10.1016\/j.crvi.2008.03.004","journal-title":"C R Biol"},{"key":"11075_CR25","doi-asserted-by":"publisher","first-page":"e1293","DOI":"10.1038\/cddis.2014.250","volume":"5","author":"L-J Liu","year":"2014","unstructured":"Liu L-J, Leung K-H, Chan DS-H et al (2014) Identification of a natural product-like STAT3 dimerization inhibitor by structure-based virtual screening. Cell Death Dis 5:e1293\u2013e1293. https:\/\/doi.org\/10.1038\/cddis.2014.250","journal-title":"Cell Death Dis"},{"key":"11075_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","volume":"20","author":"AG Atanasov","year":"2021","unstructured":"Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT (2021) Natural products in drug discovery: advances and opportunities. Nat Rev Drug Discov 20:200\u2013216. https:\/\/doi.org\/10.1038\/s41573-020-00114-z","journal-title":"Nat Rev Drug Discov"},{"key":"11075_CR27","doi-asserted-by":"publisher","first-page":"105279","DOI":"10.1016\/j.micinf.2023.105279","volume":"26","author":"R Singh","year":"2024","unstructured":"Singh R, Manna S, Nandanwar H, Purohit R (2024) Bioactives from medicinal herb against bedaquiline resistant tuberculosis: removing the dark clouds from the horizon. Microbes Infect 26:105279. https:\/\/doi.org\/10.1016\/j.micinf.2023.105279","journal-title":"Microbes Infect"},{"key":"11075_CR28","doi-asserted-by":"publisher","first-page":"e30532","DOI":"10.1002\/jcb.30532","volume":"125","author":"A Gupta","year":"2024","unstructured":"Gupta A, Purohit R (2024) Identification of potent BRD4-BD1 inhibitors using classical and steered molecular dynamics based free energy analysis. J Cell Biochem 125:e30532. https:\/\/doi.org\/10.1002\/jcb.30532","journal-title":"J Cell Biochem"},{"key":"11075_CR29","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3390\/molecules26041109","volume":"26","author":"CA Dehelean","year":"2021","unstructured":"Dehelean CA, Marcovici I, Soica C et al (2021) Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. Molecules 26:1109. https:\/\/doi.org\/10.3390\/molecules26041109","journal-title":"Molecules"},{"key":"11075_CR30","doi-asserted-by":"publisher","first-page":"110094","DOI":"10.1016\/j.jtbi.2019.110094","volume":"486","author":"V Bhardwaj","year":"2020","unstructured":"Bhardwaj V, Singh R, Singh P et al (2020) Elimination of bitter-off taste of stevioside through structure modification and computational interventions. J Theor Biol 486:110094. https:\/\/doi.org\/10.1016\/j.jtbi.2019.110094","journal-title":"J Theor Biol"},{"key":"11075_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00397","author":"E Lauti\u00e9","year":"2020","unstructured":"Lauti\u00e9 E, Russo O, Ducrot P, Boutin JA (2020) Unraveling plant natural chemical diversity for drug discovery purposes. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2020.00397","journal-title":"Front Pharmacol"},{"key":"11075_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/molecules27020349","volume":"27","author":"A Najmi","year":"2022","unstructured":"Najmi A, Javed SA, Al Bratty M, Alhazmi HA (2022) Modern approaches in the discovery and development of plant-based natural products and their analogues as potential therapeutic agents. Molecules 27:349. https:\/\/doi.org\/10.3390\/molecules27020349","journal-title":"Molecules"},{"key":"11075_CR33","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1021\/acs.jmedchem.0c01786","volume":"64","author":"P Bhutani","year":"2021","unstructured":"Bhutani P, Joshi G, Raja N et al (2021) U.S. FDA approved drugs from 2015\u2013June 2020: a perspective. J Med Chem 64:2339\u20132381. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01786","journal-title":"J Med Chem"},{"key":"11075_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.53388\/TMR20220531001","volume":"8","author":"T Omara","year":"2023","unstructured":"Omara T, Kiprop AK, Kosgei VJ (2023) Phytochemicals, polyphenols content, in vitro antioxidant and antibacterial activities of Albizia coriaria Welw ex. Oliver flowers. Tradit Med Res 8:7. https:\/\/doi.org\/10.53388\/TMR20220531001","journal-title":"Tradit Med Res"},{"key":"11075_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.53388\/TMR20220620001","volume":"8","author":"U Patangia","year":"2023","unstructured":"Patangia U, Wal A, Gupta D et al (2023) A review of the phytochemical constituents and pharmacological activities of Nagkesar (Mesua ferrea Linn). Tradit Med Res 8:14. https:\/\/doi.org\/10.53388\/TMR20220620001","journal-title":"Tradit Med Res"},{"key":"11075_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpha.2018.12.002","volume":"9","author":"R Khanam","year":"2019","unstructured":"Khanam R, Hejazi II, Shahabuddin S et al (2019) Pharmacokinetic evaluation, molecular docking and in vitro biological evaluation of 1, 3, 4-oxadiazole derivatives as potent antioxidants and STAT3 inhibitors. J Pharm Anal 9:133\u2013141. https:\/\/doi.org\/10.1016\/j.jpha.2018.12.002","journal-title":"J Pharm Anal"},{"key":"11075_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/621423","volume":"2013","author":"G Zhang","year":"2013","unstructured":"Zhang G, Li Q, Chen Q, Su S (2013) Network pharmacology: a new approach for chinese herbal medicine research. Evid-Based Complement Altern Med 2013:1\u20139. https:\/\/doi.org\/10.1155\/2013\/621423","journal-title":"Evid-Based Complement Altern Med"},{"key":"11075_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.drudis.2015.09.003","volume":"21","author":"KC Bulusu","year":"2016","unstructured":"Bulusu KC, Guha R, Mason DJ et al (2016) Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov Today 21:225\u2013238. https:\/\/doi.org\/10.1016\/j.drudis.2015.09.003","journal-title":"Drug Discov Today"},{"key":"11075_CR39","doi-asserted-by":"publisher","first-page":"836724","DOI":"10.3389\/fphar.2022.836724","volume":"13","author":"Y Hua","year":"2022","unstructured":"Hua Y, Yuan X, Shen Y-H et al (2022) Novel STAT3 inhibitors targeting STAT3 dimerization by binding to the STAT3 SH2 domain. Front Pharmacol 13:836724. https:\/\/doi.org\/10.3389\/fphar.2022.836724","journal-title":"Front Pharmacol"},{"key":"11075_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"G Madhavi Sastry","year":"2013","unstructured":"Madhavi Sastry G, Adzhigirey M, Day T et al (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8","journal-title":"J Comput Aided Mol Des"},{"key":"11075_CR41","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","volume":"55","author":"T Sterling","year":"2015","unstructured":"Sterling T, Irwin JJ (2015) ZINC 15\u2014ligand discovery for everyone. J Chem Inf Model 55:2324\u20132337. https:\/\/doi.org\/10.1021\/acs.jcim.5b00559","journal-title":"J Chem Inf Model"},{"key":"11075_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-022-10541-2","author":"BH Kumar","year":"2022","unstructured":"Kumar BH, Manandhar S, Choudhary SS et al (2022) Identification of phytochemical as a dual inhibitor of PI3K and mTOR: a structure-based computational approach. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-022-10541-2","journal-title":"Mol Divers"},{"key":"11075_CR43","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner RA, Banks JL, Murphy RB et al (2004) Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47:1739\u20131749. https:\/\/doi.org\/10.1021\/jm0306430","journal-title":"J Med Chem"},{"key":"11075_CR44","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J et al (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119:9478\u20139508. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00055","journal-title":"Chem Rev"},{"key":"11075_CR45","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ph17060725","volume":"17","author":"D Klimoszek","year":"2024","unstructured":"Klimoszek D, Jele\u0144 M, Do\u0142owy M, Morak-M\u0142odawska B (2024) Study of the lipophilicity and ADMET parameters of new anticancer diquinothiazines with pharmacophore substituents. Pharmaceuticals 17:725. https:\/\/doi.org\/10.3390\/ph17060725","journal-title":"Pharmaceuticals"},{"key":"11075_CR46","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3109\/10799893.2013.822888","volume":"33","author":"P Kirubakaran","year":"2013","unstructured":"Kirubakaran P, Karthikeyan M (2013) Pharmacophore modeling, 3D-QSAR and DFT studies of IWR small-molecule inhibitors of Wnt response. J Recept Signal Transduct 33:276\u2013285. https:\/\/doi.org\/10.3109\/10799893.2013.822888","journal-title":"J Recept Signal Transduct"},{"key":"11075_CR47","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3390\/ijms13010427","volume":"13","author":"P Szyma\u0144ski","year":"2011","unstructured":"Szyma\u0144ski P, Markowicz M, Mikiciuk-Olasik E (2011) Adaptation of high-throughput screening in drug discovery\u2014toxicological screening tests. Int J Mol Sci 13:427\u2013452. https:\/\/doi.org\/10.3390\/ijms13010427","journal-title":"Int J Mol Sci"},{"key":"11075_CR48","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"RA Friesner","year":"2006","unstructured":"Friesner RA, Murphy RB, Repasky MP et al (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein\u2212ligand complexes. J Med Chem 49:6177\u20136196. https:\/\/doi.org\/10.1021\/jm051256o","journal-title":"J Med Chem"},{"key":"11075_CR49","doi-asserted-by":"publisher","first-page":"5465","DOI":"10.1080\/07391102.2022.2087736","volume":"41","author":"V Chahal","year":"2023","unstructured":"Chahal V, Kakkar R (2023) A combination strategy of structure-based virtual screening, MM-GBSA, cross docking, molecular dynamics and metadynamics simulations used to investigate natural compounds as potent and specific inhibitors of tumor linked human carbonic anhydrase IX. J Biomol Struct Dyn 41:5465\u20135480. https:\/\/doi.org\/10.1080\/07391102.2022.2087736","journal-title":"J Biomol Struct Dyn"},{"key":"11075_CR50","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2174\/1568026616666161117112604","volume":"17","author":"X Zhang","year":"2017","unstructured":"Zhang X, Perez-Sanchez H, Lightstone FC (2017) A comprehensive docking and MM\/GBSA rescoring study of ligand recognition upon binding antithrombin. Curr Top Med Chem 17:1631\u20131639. https:\/\/doi.org\/10.2174\/1568026616666161117112604","journal-title":"Curr Top Med Chem"},{"key":"11075_CR51","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2174\/0115680266280005231207105900","volume":"24","author":"M Chen","year":"2024","unstructured":"Chen M, Yang J, Tang C et al (2024) Improving ADMET prediction accuracy for candidate drugs: factors to consider in QSPR modeling approaches. Curr Top Med Chem 24:222\u2013242. https:\/\/doi.org\/10.2174\/0115680266280005231207105900","journal-title":"Curr Top Med Chem"},{"key":"11075_CR52","doi-asserted-by":"publisher","first-page":"127670","DOI":"10.1016\/j.molstruc.2019.127670","volume":"1205","author":"A Mohan","year":"2020","unstructured":"Mohan A, Kirubakaran R, Parray JA et al (2020) Ligand-based pharmacophore filtering, atom based 3D-QSAR, virtual screening and ADME studies for the discovery of potential ck2 inhibitors. J Mol Struct 1205:127670. https:\/\/doi.org\/10.1016\/j.molstruc.2019.127670","journal-title":"J Mol Struct"},{"key":"11075_CR53","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","volume":"114","author":"AS Nagle","year":"2014","unstructured":"Nagle AS, Khare S, Kumar AB et al (2014) Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem Rev 114:11305\u201311347. https:\/\/doi.org\/10.1021\/cr500365f","journal-title":"Chem Rev"},{"key":"11075_CR54","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0960-894X(00)00172-4","volume":"10","author":"WL Jorgensen","year":"2000","unstructured":"Jorgensen WL, Duffy EM (2000) Prediction of drug solubility from Monte Carlo simulations. Bioorg Med Chem Lett 10:1155\u20131158. https:\/\/doi.org\/10.1016\/S0960-894X(00)00172-4","journal-title":"Bioorg Med Chem Lett"},{"key":"11075_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2024.2305316","author":"R Muthuraj","year":"2024","unstructured":"Muthuraj R, Gopal D, Ahmed I, Chandrasekaran J (2024) Insightful t-SNE guided exploration spotlighting Palbociclib and Ribociclib analogues as novel WEE1 kinase inhibitory candidates. J Biomol Struct Dyn. https:\/\/doi.org\/10.1080\/07391102.2024.2305316","journal-title":"J Biomol Struct Dyn"},{"key":"11075_CR56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/molecules28031035","volume":"28","author":"L Silva","year":"2023","unstructured":"Silva L, Ferreira E, Maryam et al (2023) Galantamine based novel acetylcholinesterase enzyme inhibitors: a molecular modeling design approach. Molecules 28:1035. https:\/\/doi.org\/10.3390\/molecules28031035","journal-title":"Molecules"},{"key":"11075_CR57","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41557-024-01630-w","volume":"16","author":"S Ambadi Thody","year":"2024","unstructured":"Ambadi Thody S, Clements HD, Baniasadi H et al (2024) Small-molecule properties define partitioning into biomolecular condensates. Nat Chem 16:1794\u20131802. https:\/\/doi.org\/10.1038\/s41557-024-01630-w","journal-title":"Nat Chem"},{"key":"11075_CR58","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1517\/17460441.2013.749853","volume":"8","author":"Y Yang","year":"2013","unstructured":"Yang Y, Lightstone FC, Wong SE (2013) Approaches to efficiently estimate solvation and explicit water energetics in ligand binding: the use of WaterMap. Expert Opin Drug Discov 8:277\u2013287. https:\/\/doi.org\/10.1517\/17460441.2013.749853","journal-title":"Expert Opin Drug Discov"},{"key":"11075_CR59","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1021\/acs.jcim.6b00483","volume":"57","author":"M Schauperl","year":"2017","unstructured":"Schauperl M, Czodrowski P, Fuchs JE et al (2017) Binding pose flip explained via enthalpic and entropic contributions. J Chem Inf Model 57:345\u2013354. https:\/\/doi.org\/10.1021\/acs.jcim.6b00483","journal-title":"J Chem Inf Model"},{"key":"11075_CR60","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/ci3005786","volume":"53","author":"AT Garc\u00eda-Sosa","year":"2013","unstructured":"Garc\u00eda-Sosa AT (2013) Hydration properties of ligands and drugs in protein binding sites: tightly-bound, bridging water molecules and their effects and consequences on molecular design strategies. J Chem Inf Model 53:1388\u20131405. https:\/\/doi.org\/10.1021\/ci3005786","journal-title":"J Chem Inf Model"},{"key":"11075_CR61","doi-asserted-by":"publisher","first-page":"31488","DOI":"10.1038\/srep31488","volume":"6","author":"LL Duan","year":"2016","unstructured":"Duan LL, Feng GQ, Zhang QG (2016) Large-scale molecular dynamics simulation: effect of polarization on thrombin-ligand binding energy. Sci Rep 6:31488. https:\/\/doi.org\/10.1038\/srep31488","journal-title":"Sci Rep"},{"key":"11075_CR62","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1021\/acs.jctc.8b00874","volume":"15","author":"J Jung","year":"2019","unstructured":"Jung J, Kobayashi C, Sugita Y (2019) Optimal temperature evaluation in molecular dynamics simulations with a large time step. J Chem Theory Comput 15:84\u201394. https:\/\/doi.org\/10.1021\/acs.jctc.8b00874","journal-title":"J Chem Theory Comput"},{"key":"11075_CR63","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1021\/ar010018u","volume":"35","author":"P Carloni","year":"2002","unstructured":"Carloni P, Rothlisberger U, Parrinello M (2002) The role and perspective of ab initio molecular dynamics in the study of biological systems. Acc Chem Res 35:455\u2013464. https:\/\/doi.org\/10.1021\/ar010018u","journal-title":"Acc Chem Res"},{"key":"11075_CR64","doi-asserted-by":"publisher","first-page":"12800","DOI":"10.1021\/ja504441h","volume":"136","author":"V Conti Nibali","year":"2014","unstructured":"Conti Nibali V, Havenith M (2014) New insights into the role of water in biological function: studying solvated biomolecules using terahertz absorption spectroscopy in conjunction with molecular dynamics simulations. J Am Chem Soc 136:12800\u201312807. https:\/\/doi.org\/10.1021\/ja504441h","journal-title":"J Am Chem Soc"},{"key":"11075_CR65","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00210-015-1150-1","volume":"388","author":"T Reuter","year":"2015","unstructured":"Reuter T, Warta R, Theile D et al (2015) Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn Schmiedebergs Arch Pharmacol 388:1141\u20131150. https:\/\/doi.org\/10.1007\/s00210-015-1150-1","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"11075_CR66","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ddtec.2016.05.001","volume":"19","author":"S Appikonda","year":"2016","unstructured":"Appikonda S, Thakkar KN, Barton MC (2016) Regulation of gene expression in human cancers by TRIM24. Drug Discov Today Technol 19:57\u201363. https:\/\/doi.org\/10.1016\/j.ddtec.2016.05.001","journal-title":"Drug Discov Today Technol"},{"key":"11075_CR67","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41417-021-00419-0","volume":"29","author":"E Kang","year":"2022","unstructured":"Kang E, Kim K, Jeon SY et al (2022) Targeting CLK4 inhibits the metastasis and progression of breast cancer by inactivating TGF-\u03b2 pathway. Cancer Gene Ther 29:1168\u20131180. https:\/\/doi.org\/10.1038\/s41417-021-00419-0","journal-title":"Cancer Gene Ther"},{"key":"11075_CR68","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/cells7090133","volume":"7","author":"J Concetti","year":"2018","unstructured":"Concetti J, Wilson CL (2018) NFKB1 and cancer: friend or foe? Cells 7:133. https:\/\/doi.org\/10.3390\/cells7090133","journal-title":"Cells"},{"key":"11075_CR69","doi-asserted-by":"publisher","first-page":"e1003552","DOI":"10.1371\/journal.pgen.1003552","volume":"9","author":"Y Luo","year":"2013","unstructured":"Luo Y, Kaz AM, Kanngurn S et al (2013) NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer. PLoS Genet 9:e1003552. https:\/\/doi.org\/10.1371\/journal.pgen.1003552","journal-title":"PLoS Genet"},{"key":"11075_CR70","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.21037\/tcr.2017.10.48","volume":"6","author":"W Huang","year":"2017","unstructured":"Huang W, Wang Y, Zeng G et al (2017) Study the effect of CTSD interaction proteins in invasion and metastasis of nasopharyngeal carcinoma. Transl Cancer Res 6:1236\u20131247. https:\/\/doi.org\/10.21037\/tcr.2017.10.48","journal-title":"Transl Cancer Res"},{"key":"11075_CR71","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/cancers11101548","volume":"11","author":"W Klu\u017aniak","year":"2019","unstructured":"Klu\u017aniak W, Woko\u0142orczyk D, Rusak B et al (2019) Inherited variants in BLM and the risk and clinical characteristics of breast cancer. Cancers (Basel) 11:1548. https:\/\/doi.org\/10.3390\/cancers11101548","journal-title":"Cancers (Basel)"},{"key":"11075_CR72","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ijc.29028","volume":"136","author":"X Li","year":"2015","unstructured":"Li X, Zhang B, Wu Q et al (2015) Interruption of KLF5 acetylation converts its function from tumor suppressor to tumor promoter in prostate cancer cells. Int J Cancer 136:536\u2013546. https:\/\/doi.org\/10.1002\/ijc.29028","journal-title":"Int J Cancer"},{"key":"11075_CR73","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/cas.13990","volume":"110","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Yokota A, Harada H, Huang G (2019) Hypoxia\/pseudohypoxia-mediated activation of hypoxia-inducible factor-1\u03b1 in cancer. Cancer Sci 110:1510\u20131517. https:\/\/doi.org\/10.1111\/cas.13990","journal-title":"Cancer Sci"},{"key":"11075_CR74","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1172\/JCI65521","volume":"123","author":"M-H Kim","year":"2013","unstructured":"Kim M-H, Kim H-B, Yoon SP et al (2013) Colon cancer progression is driven by APEX1-mediated upregulation of Jagged. J Clin Invest 123:3211\u20133230. https:\/\/doi.org\/10.1172\/JCI65521","journal-title":"J Clin Invest"},{"key":"11075_CR75","doi-asserted-by":"publisher","first-page":"101364","DOI":"10.1016\/j.tranon.2022.101364","volume":"18","author":"M-J Sanaei","year":"2022","unstructured":"Sanaei M-J, Razi S, Pourbagheri-Sigaroodi A, Bashash D (2022) The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles. Transl Oncol 18:101364. https:\/\/doi.org\/10.1016\/j.tranon.2022.101364","journal-title":"Transl Oncol"},{"key":"11075_CR76","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41420-023-01502-1","volume":"9","author":"A Antona","year":"2023","unstructured":"Antona A, Leo G, Favero F et al (2023) Targeting lysine-specific demethylase 1 (KDM1A\/LSD1) impairs colorectal cancer tumorigenesis by affecting cancer cells stemness, motility, and differentiation. Cell Death Discov 9:201. https:\/\/doi.org\/10.1038\/s41420-023-01502-1","journal-title":"Cell Death Discov"},{"key":"11075_CR77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.7150\/jca.64017","volume":"13","author":"T Wang","year":"2022","unstructured":"Wang T, Lu J, Wang R et al (2022) TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p. J Cancer 13:589\u2013601. https:\/\/doi.org\/10.7150\/jca.64017","journal-title":"J Cancer"},{"key":"11075_CR78","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/ncb3124","volume":"17","author":"LK Boroughs","year":"2015","unstructured":"Boroughs LK, DeBerardinis RJ (2015) Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17:351\u2013359. https:\/\/doi.org\/10.1038\/ncb3124","journal-title":"Nat Cell Biol"},{"key":"11075_CR79","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1646905","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Chen B, Chen S et al (2020) Applications of network pharmacology in traditional Chinese medicine research. Evid-Based Complement Altern Med. https:\/\/doi.org\/10.1155\/2020\/1646905","journal-title":"Evid-Based Complement Altern Med"},{"key":"11075_CR80","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1210\/er.2017-00211","volume":"39","author":"RL Smith","year":"2018","unstructured":"Smith RL, Soeters MR, W\u00fcst RCI, Houtkooper RH (2018) Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. Endocr Rev 39:489\u2013517. https:\/\/doi.org\/10.1210\/er.2017-00211","journal-title":"Endocr Rev"},{"key":"11075_CR81","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1128\/MMBR.00025-13","volume":"77","author":"WC van Heeswijk","year":"2013","unstructured":"van Heeswijk WC, Westerhoff HV, Boogerd FC (2013) Nitrogen assimilation in Escherichia coli: putting molecular data into a systems perspective. Microbiol Mol Biol Rev 77:628\u2013695. https:\/\/doi.org\/10.1128\/MMBR.00025-13","journal-title":"Microbiol Mol Biol Rev"},{"key":"11075_CR82","doi-asserted-by":"publisher","first-page":"5949","DOI":"10.1021\/cr300174a","volume":"112","author":"M Hakim","year":"2012","unstructured":"Hakim M, Broza YY, Barash O et al (2012) Volatile organic compounds of lung cancer and possible biochemical pathways. Chem Rev 112:5949\u20135966. https:\/\/doi.org\/10.1021\/cr300174a","journal-title":"Chem Rev"},{"key":"11075_CR83","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-1-4615-3336-8_5","volume-title":"Evolutionary biology","author":"PA Parsons","year":"1992","unstructured":"Parsons PA (1992) Evolutionary adaptation and stress. In: Evolutionary biology. Springer, Boston, pp 191\u2013223"},{"key":"11075_CR84","first-page":"922","volume":"13","author":"VI Lushchak","year":"2014","unstructured":"Lushchak VI (2014) Classification of oxidative stress based on its intensity. EXCLI J 13:922\u2013937","journal-title":"EXCLI J"},{"key":"11075_CR85","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/biomedicines12071621","volume":"12","author":"J Ma","year":"2024","unstructured":"Ma J, Veeragoni D, Ghosh H et al (2024) Superior anticancer and antifungal activities of new sulfanyl-substituted niclosamide derivatives. Biomedicines 12:1621. https:\/\/doi.org\/10.3390\/biomedicines12071621","journal-title":"Biomedicines"},{"key":"11075_CR86","doi-asserted-by":"publisher","first-page":"115564","DOI":"10.1016\/j.bcp.2023.115564","volume":"212","author":"N Wei","year":"2023","unstructured":"Wei N, Burnett J, Crocker DL et al (2023) Quassinoid analogs exert potent antitumor activity via reversible protein biosynthesis inhibition in human colorectal cancer. Biochem Pharmacol 212:115564. https:\/\/doi.org\/10.1016\/j.bcp.2023.115564","journal-title":"Biochem Pharmacol"},{"key":"11075_CR87","doi-asserted-by":"publisher","first-page":"117382","DOI":"10.1016\/j.bmc.2023.117382","volume":"91","author":"X Yang","year":"2023","unstructured":"Yang X, Xu L, Yang L, Xu S (2023) Research progress of STAT3-based dual inhibitors for cancer therapy. Bioorg Med Chem 91:117382. https:\/\/doi.org\/10.1016\/j.bmc.2023.117382","journal-title":"Bioorg Med Chem"},{"key":"11075_CR88","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202400254","author":"C Frezza","year":"2024","unstructured":"Frezza C, Nicolosi RM, Brasili E et al (2024) Occurrence and Biological Activities of Seco -Iridoids from Jasminum L. Chem Biodivers. https:\/\/doi.org\/10.1002\/cbdv.202400254","journal-title":"Chem Biodivers"},{"key":"11075_CR89","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3390\/plants10061089","volume":"10","author":"A Balkrishna","year":"2021","unstructured":"Balkrishna A, Rohela A, Kumar A et al (2021) Mechanistic insight into antimicrobial and antioxidant potential of jasminum species: a herbal approach for disease management. Plants 10:1089. https:\/\/doi.org\/10.3390\/plants10061089","journal-title":"Plants"},{"key":"11075_CR90","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.1111\/febs.16116","volume":"289","author":"M Diallo","year":"2022","unstructured":"Diallo M, Herrera F (2022) The role of understudied post-translational modifications for the behavior and function of signal transducer and activator of transcription 3. FEBS J 289:6235\u20136255. https:\/\/doi.org\/10.1111\/febs.16116","journal-title":"FEBS J"},{"key":"11075_CR91","doi-asserted-by":"publisher","first-page":"102023","DOI":"10.1016\/j.tranon.2024.102023","volume":"46","author":"S Kumar","year":"2024","unstructured":"Kumar S, Arwind DA, Kumar BH et al (2024) Inhibition of STAT3: a promising approach to enhancing the efficacy of chemotherapy in medulloblastoma. Transl Oncol 46:102023. https:\/\/doi.org\/10.1016\/j.tranon.2024.102023","journal-title":"Transl Oncol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-024-11075-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-024-11075-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:29:46Z","timestamp":1763728186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-024-11075-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11075"],"URL":"https:\/\/doi.org\/10.1007\/s11030-024-11075-5","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,9]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}